Monopar Therapeutics — Director's Dealing 2018

Jan 8, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Monopar Therapeutics (NONE)
CIK: 0001645469
Period of Report: 2018-01-08

Reporting Person: STARR CHRISTOPHER M (N/A)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common stock	29400	Indirect
Common stock	20000	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock options	$0.001		Common stock (84000)		Direct
Stock options	$0.001		Common stock (84000)		Direct

Footnotes

F1: 29,400 shares of Common Stock held by the Christopher M. Starr and Sheri L. Starr Revocable Trust over which Dr. Starr serves as Trustee.

F2: 20,000 shares of Common Stock held by the Christopher M. Starr and Sheri L. Starr Revocable Trust over which Dr. Starr serves as Trustee.

F3: Reflects the issuance of options to purchase up to 84,000 shares of common stock granted to Dr. Starr on April 4, 2016 for his services as a director of Monopar Therapeutics. The options vested 50% upon grant date, 25% upon the 6-month anniversary of grant date, and 25% upon the 1-year anniversary of grant date. The options each expire on April 3, 2026.

F4: Reflects the issuance of options to purchase up to 84,000 shares of common stock granted to Dr. Starr on February 20, 2017 for his services as a director of Monopar Therapeutics. The options will vest 6/48ths at the six-month anniversary of grant date and 1/48th per month thereafter. The options each expire on February 19, 2027.